PF-Atlas › Clinical Trials › NCT07121413

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis

SV001 · Phase 2

Registry ID

NCT07121413

Phase

Phase 2

Status

Recruiting

Drug / intervention

SV001

Sponsor

Shanghai Synvida Biotechnology Co.,Ltd.

Start

2025-11-04

Enrollment

Locations

About this trial

The purpose of this study is to evaluate the safety, tolerability, PK and immunogenicity of SV001 in patients with idiopathic pulmonary fibrosis.

View NCT07121413 on ClinicalTrials.gov →

Explore related

All SV001 trials All IPF trials

Related trials

SV001 — NCT06267183

Medical disclaimer. This page summarizes public trial data for NCT07121413 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.